Fig. 1.

Dose-response immunogenicity of human adenovirus in mice and macaques. Immunological potency of human Ad vectors encoding for HIV-1 gag in BALB/c mice (A). Five animals per group were immunized intramuscularly with escalating doses of each Ad vector. IFN-γ ELISpot was performed on splenocytes collected three weeks later using as antigen a 9mer peptide encoding the HIV gag major H-2 Kd CD8 epitope (AMQMLKETI). Each bar represents the relative potency defined as the minimal Ad vectors dose capable of inducing a HIV-1 gag-specific T-cell response in at least 2 out of 5 animals. Data are shown as the reciprocal of minimal dose. The adenovirus serogroups are shown with different bar colours (white=group B, black=group C, dark grey=group D).

Immunological potency of human Ad vectors in macaques (B). Three animals per group were vaccinated intramuscularly with 10¹⁰ and 10⁸ vp of each Ad vector encoding for HIV-1 gag. Four weeks after vaccination, T cell responses to a 15mer peptide pool covering gag were measured by IFN-γ ELISpot on PBMC. Data are expressed as IFNγ Spot Forming Cells (SFC) per million PBMC. The mean responses + SEM are shown for each immunization group.